(Alliance News) - Fusion Antibodies PLC on Wednesday announced the approval of a grant funding application to The Northern Ireland Precision Biomarkers & Therapeutics consortium, of which it is a member. Read More
(Alliance News) - Fusion Antibodies PLC on Tuesday said its loss narrowed in the first half of its current financial year, as revenue more than doubled. Read More
Fusion Antibodies PLC - Belfast-based contract researcher that provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Expects revenue of around GBP1.2 million for the six months to September 30, more than doubling from GBP541,000 at the same time last year. Its gross margin is expected to be 29%, compared to negative 16% the year prior. Fusion Antibodies expands its collaboration agreement with the National Cancer Institute in the six-month period to include the company's humanisation of the NCI's existing camelid nanobodies, and secures a new contract for an antibody based therapeutic with an unnamed US-based biotechnology company. It is also contracted to develop a bespoke OptiPhage library for an unnamed client. The company remains on track with its strategic goals. Read More
(Alliance News) - Fusion Antibodies PLC on Wednesday said it is expanding its collaboration agreement with the National Cancer Institute. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Fusion Antibodies PLC on Monday said that it has signed a commercial contract to develop an OptiPhage library for a non-human antibody species. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Fusion Antibodies PLC - Belfast-based contract researcher, which provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Conditionally raises GBP1.4 million before expenses via placing of 34.4 million shares at 4 pence each. The issue price represents a discount of 5.9% to Fusion's closing mid-market share price on Tuesday. Further, it intends to issue 1.5 million new shares to certain directors in lieu of or in satisfaction of salary and fees due to them and which shall be issued immediately following publication of its announcement. Also intends to grant a total of up to 3.8 million new share options to staff and senior management. Read More
(Alliance News) - Fusion Antibodies PLC on Tuesday said it has won a follow-on project under a collaborative research and development agreement with an unnamed "US-based biotechnology company". Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday. Read More
(Alliance News) - Fusion Antibodies PLC on Thursday announced the receipt of a research & development tax credit from UK HM Revenue & Customs for work performed on the development of its OptiMAL platform and other projects in bioinformatics. Read More
(Alliance News) - Stock prices in London closed lower on Monday, with miners and oil firms holding down the FTSE 100 index. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday. Read More
(Alliance News) - Fusion Antibodies PLC on Monday reported a widened loss and reduced revenue for its latest half year, but said its growth prospects are "increasingly positive". Read More
(Alliance News) - Fusion Antibodies PLC on Tuesday said it has signed a collaboration agreement with the US National Cancer Institute to use its OptiMAL product to discover novel antibodies to treat certain targets. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday. Read More